Day: May 28, 2021

CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases Sequencing data to be...

error: Content is protected !!